These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 10391849

  • 1. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses.
    Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB.
    Clin Diagn Lab Immunol; 1999 Jul; 6(4):494-8. PubMed ID: 10391849
    [Abstract] [Full Text] [Related]

  • 2. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP, Cannon MJ.
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM.
    J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
    [Abstract] [Full Text] [Related]

  • 4. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, Wagner H, Lipford GB.
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [Abstract] [Full Text] [Related]

  • 5. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.
    Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA.
    Cancer Res; 1999 Mar 15; 59(6):1184-7. PubMed ID: 10096544
    [Abstract] [Full Text] [Related]

  • 6. Induction of rat CD4+ proliferative and mouse CD8+ cytotoxic T-cell lines specific for human papillomavirus type 16 antigens.
    Bagot M, Charue D, Cerni C, Revuz J, Meneguzzi G.
    Res Virol; 1996 Mar 15; 147(5):301-11. PubMed ID: 8880999
    [Abstract] [Full Text] [Related]

  • 7. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA, Jordanova ES, van Poelgeest MI, van den Akker BE, van der Burg SH, Kenter GG, Fleuren GJ.
    Int J Cancer; 2007 Dec 15; 121(12):2711-5. PubMed ID: 17724722
    [Abstract] [Full Text] [Related]

  • 8. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
    Tong WW, Shepherd K, Garland S, Meagher A, Templeton DJ, Fairley CK, Jin F, Poynten IM, Zaunders J, Hillman RJ, Grulich AE, Kelleher AD, Carr A, Study of the Prevention of Anal Cancer (SPANC) team.
    J Infect Dis; 2015 Feb 01; 211(3):405-15. PubMed ID: 25139018
    [Abstract] [Full Text] [Related]

  • 9. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
    Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.
    Clin Cancer Res; 2004 May 01; 10(9):2954-61. PubMed ID: 15131030
    [Abstract] [Full Text] [Related]

  • 10. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC.
    Clin Cancer Res; 2003 Nov 01; 9(14):5205-13. PubMed ID: 14614000
    [Abstract] [Full Text] [Related]

  • 11. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI.
    Cancer Res; 2002 Dec 15; 62(24):7234-40. PubMed ID: 12499264
    [Abstract] [Full Text] [Related]

  • 12. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL.
    Cancer Res; 2003 Sep 15; 63(18):6032-41. PubMed ID: 14522932
    [Abstract] [Full Text] [Related]

  • 13. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC.
    J Virol; 2004 Aug 15; 78(16):8468-76. PubMed ID: 15280455
    [Abstract] [Full Text] [Related]

  • 14. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y.
    J Immunol; 2001 Dec 01; 167(11):6471-9. PubMed ID: 11714814
    [Abstract] [Full Text] [Related]

  • 15. Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16.
    Sarkar AK, Tortolero-Luna G, Nehete PN, Arlinghaus RB, Mitchell MF, Sastry KJ.
    Viral Immunol; 1995 Dec 01; 8(3):165-74. PubMed ID: 8833270
    [Abstract] [Full Text] [Related]

  • 16. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S.
    Cancer Res; 1997 Nov 01; 57(21):4855-61. PubMed ID: 9354449
    [Abstract] [Full Text] [Related]

  • 17. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.
    Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellström I, Hellström KE.
    J Immunol; 1992 Apr 15; 148(8):2617-21. PubMed ID: 1313847
    [Abstract] [Full Text] [Related]

  • 18. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY, Chen CA, Lee CN, Chang MC, Su YN, Lin YC, Hsieh CY, Cheng WF.
    Gynecol Oncol; 2007 Dec 15; 107(3):404-12. PubMed ID: 17905417
    [Abstract] [Full Text] [Related]

  • 19. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE, Latchman YE, Balint JP, Lee JH, Gabitzsch ES, Jones FR.
    Cancer Gene Ther; 2015 Sep 15; 22(9):454-62. PubMed ID: 26337747
    [Abstract] [Full Text] [Related]

  • 20. E7-specific cytotoxic T cell tolerance in HPV-transgenic mice.
    Borchers A, Braspenning J, Meijer J, Osen W, Gissmann L, Jochmus I.
    Arch Virol; 1999 Sep 15; 144(8):1539-56. PubMed ID: 10486109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.